CRVO vs. SGMT, INCR, CNTX, CTMX, SYRS, CYBN, CRVS, RENB, OPTN, and IMAB
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Sagimet Biosciences (SGMT), InterCure (INCR), Context Therapeutics (CNTX), CytomX Therapeutics (CTMX), Syros Pharmaceuticals (SYRS), Cybin (CYBN), Corvus Pharmaceuticals (CRVS), Renovaro (RENB), OptiNose (OPTN), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.
Sagimet Biosciences (NASDAQ:SGMT) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
CervoMed has higher revenue and earnings than Sagimet Biosciences.
87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by insiders. Comparatively, 2.0% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Sagimet Biosciences had 8 more articles in the media than CervoMed. MarketBeat recorded 10 mentions for Sagimet Biosciences and 2 mentions for CervoMed. Sagimet Biosciences' average media sentiment score of 1.88 beat CervoMed's score of 0.85 indicating that CervoMed is being referred to more favorably in the news media.
Sagimet Biosciences' return on equity of -45.48% beat CervoMed's return on equity.
Sagimet Biosciences presently has a consensus target price of $39.20, indicating a potential upside of 664.13%. CervoMed has a consensus target price of $57.50, indicating a potential upside of 209.64%. Given CervoMed's higher probable upside, research analysts plainly believe Sagimet Biosciences is more favorable than CervoMed.
Sagimet Biosciences received 13 more outperform votes than CervoMed when rated by MarketBeat users.
Summary
Sagimet Biosciences beats CervoMed on 8 of the 12 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
